雷奈酸锶治疗老年男性骨质疏松性骨痛的疗效和安全性评价

The evaluation of efficacy and safety of strontium ranelate on osteoporotic bone pain and bone mineral density in male osteoporosis

目的 观察雷奈酸锶在男性骨质疏松症治疗中对骨痛的疗效,并评价其安全性.方法 共纳入58例男性骨质疏松症患者,其中26例雷奈酸锶组,32例为钙剂组,分别测定两组患者治疗前后腰背部视觉疼痛模拟评分（VAS评分）、L1 ～L4椎体和Wards三角的骨密度值,并观察两组骨质疏松性骨折的发生率及服药后的不良反应.结果 雷奈酸锶组患者治疗后6月及12月的VAS评分明显改善,低于钙剂组（P＜0.001）;雷奈酸锶组L1 ～L4椎体和Wards三角的骨密度值及T值在治疗后较治疗前上升显著,明显优于钙剂组（P＜0.001）.雷奈酸锶组患者的主要不良反应为恶心及腹泻,钙剂组主要为便秘.结论 雷奈酸锶能有效地提高骨质量和缓解骨痛,副反应少,是治疗男性骨质疏松性骨痛的良好选择.

Objective To evaluate the efficacy and safety of strontium ranelate on bone pain during the treatment for male osteoporosis. Methods Fifty-eight elderly osteoporosis men were divided into strontium ranelate group （SR group, 26 cases） and calcium group （control group, 32 cases）. Visualanalog scale （VAS） scores of the lumbar and back pain, bone mineral density （BMD） and T scores of the lumbar vertebra 1-4 and the Ward＇s triangle were determined. The incidence of osteoporotic fracture and side effects after drug treatment in both groups were also observed. Results The VAS scores in SR group were obviously improved,and were lower than those in control group （P〈 0.001 ）. The BMD values of the lumbar venebral-4 and Ward＇s triangle significantly increased in SR group after treatment compared to those before the treatment, and the curative effects of strontium ranelate on SR group was obviously better than effects of calcium on control group （P〈0.001）. The adverse events were nausea and vomiting and erythra in SR group, and constipation in control group. Conclusion Strontium ranelate can effectively improve bone mineral density and ameliorate the chronic low back pain, which is a remarkable treatment for male patients with primary osteoporosis.